The global Live Attenuated Influenza Vaccine (LAIV) market growth is projected to reach US$ 8858 million in 2025 to US$ 12950 million in 2031; it is expected to grow at a CAGR of 6.5% from 2025 to 2031.

Global Live Attenuated Influenza Vaccine (LAIV) Market Trends And Outlook 2025-31

The global Live Attenuated Influenza Vaccine (LAIV) market size is predicted to grow from US$ 8858 million in 2025 to US$ 12950 million in 2031; it is expected to grow at a CAGR of 6.5% from 2025 to 2031. A Live Attenuated Influenza Vaccine (LAIV), also known as the nasal spray or intranasal flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response. Evolving Vaccine Formulations: The LAIV formulation changes annually to match the prevalent influenza virus strains. Researchers continually monitor and adapt the vaccine to ensure it provides protection against the most relevant strains. This requires ongoing research and development efforts. Preference for Non-Invasive Vaccination: The nasal spray administration method of LAIV is preferred by some individuals, particularly children and those who are averse to needles. This preference has driven demand for LAIV, especially among pediatric populations. Efficacy and Effectiveness Research: Ongoing research is aimed at improving the effectiveness and stability of LAIV. Ensuring the vaccines effectiveness is crucial in maintaining public confidence and its role in influenza prevention. Enhanced Cold Chain Management: As LAIV is a live vaccine, it requires specific storage and transport conditions to maintain its viability. Advances in cold chain management are essential to preserve the vaccines effectiveness. Global Variations in Approval: Approval and recommendations for LAIV can vary by country and region. Some countries may be more enthusiastic about LAIV, while others may have specific guidelines and restrictions regarding its use. Infinity Market Research newest research report, the ?Live Attenuated Influenza Vaccine (LAIV) Industry Forecast? looks at past sales and reviews total world Live Attenuated Influenza Vaccine (LAIV) sales in 2024, providing a comprehensive analysis by region and market sector of projected Live Attenuated Influenza Vaccine (LAIV) sales for 2025 through 2031. With Live Attenuated Influenza Vaccine (LAIV) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Live Attenuated Influenza Vaccine (LAIV) industry. This Insight Report provides a comprehensive analysis of the global Live Attenuated Influenza Vaccine (LAIV) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Live Attenuated Influenza Vaccine (LAIV) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Live Attenuated Influenza Vaccine (LAIV) market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Live Attenuated Influenza Vaccine (LAIV) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Live Attenuated Influenza Vaccine (LAIV). This report presents a comprehensive overview, market shares, and growth opportunities of Live Attenuated Influenza Vaccine (LAIV) market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Trivalent Flu Vaccine &nbsp;&nbsp;&nbsp; Quadrivalent Flu Vaccine Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Clinic &nbsp;&nbsp;&nbsp; Public Health Agency &nbsp;&nbsp;&nbsp; Other This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Sanofi Pasteur &nbsp;&nbsp;&nbsp; AstraZeneca &nbsp;&nbsp;&nbsp; CSL &nbsp;&nbsp;&nbsp; Abbott &nbsp;&nbsp;&nbsp; GlaxoSmithKline &nbsp;&nbsp;&nbsp; Serum Institute &nbsp;&nbsp;&nbsp; Fluenz Tetra &nbsp;&nbsp;&nbsp; Cytiva &nbsp;&nbsp;&nbsp; BioDiem &nbsp;&nbsp;&nbsp; FluMist &nbsp;&nbsp;&nbsp; GSK &nbsp;&nbsp;&nbsp; ChangChun High & New Technology &nbsp;&nbsp;&nbsp; BCHT Biotechnology Key Questions Addressed in this Report What is the 10-year outlook for the global Live Attenuated Influenza Vaccine (LAIV) market? What factors are driving Live Attenuated Influenza Vaccine (LAIV) market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Live Attenuated Influenza Vaccine (LAIV) market opportunities vary by end market size? How does Live Attenuated Influenza Vaccine (LAIV) break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Live Attenuated Influenza Vaccine (LAIV) by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Live Attenuated Influenza Vaccine (LAIV) by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Live Attenuated Influenza Vaccine (LAIV) Segment by Type &nbsp;2.2.1 Trivalent Flu Vaccine &nbsp;2.2.2 Quadrivalent Flu Vaccine &nbsp;2.3 Live Attenuated Influenza Vaccine (LAIV) Sales by Type &nbsp;2.3.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Type (2020-2025) &nbsp;2.4 Live Attenuated Influenza Vaccine (LAIV) Segment by Application &nbsp;2.4.1 Hospital &nbsp;2.4.2 Clinic &nbsp;2.4.3 Public Health Agency &nbsp;2.4.4 Other &nbsp;2.5 Live Attenuated Influenza Vaccine (LAIV) Sales by Application &nbsp;2.5.1 Global Live Attenuated Influenza Vaccine (LAIV) Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Live Attenuated Influenza Vaccine (LAIV) Breakdown Data by Company &nbsp;3.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Company (2020-2025) &nbsp;3.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Company &nbsp;3.4 Key Manufacturers Live Attenuated Influenza Vaccine (LAIV) Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Live Attenuated Influenza Vaccine (LAIV) Product Location Distribution &nbsp;3.4.2 Players Live Attenuated Influenza Vaccine (LAIV) Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Live Attenuated Influenza Vaccine (LAIV) by Geographic Region &nbsp;4.1 World Historic Live Attenuated Influenza Vaccine (LAIV) Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Live Attenuated Influenza Vaccine (LAIV) Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Live Attenuated Influenza Vaccine (LAIV) Sales Growth &nbsp;4.4 APAC Live Attenuated Influenza Vaccine (LAIV) Sales Growth &nbsp;4.5 Europe Live Attenuated Influenza Vaccine (LAIV) Sales Growth &nbsp;4.6 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Growth 5 Americas &nbsp;5.1 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Country &nbsp;5.1.1 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025) &nbsp;5.1.2 Americas Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2020-2025) &nbsp;5.2 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2020-2025) &nbsp;5.3 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Region &nbsp;6.1.1 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2020-2025) &nbsp;6.1.2 APAC Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2020-2025) &nbsp;6.2 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2020-2025) &nbsp;6.3 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Live Attenuated Influenza Vaccine (LAIV) by Country &nbsp;7.1.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025) &nbsp;7.1.2 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2020-2025) &nbsp;7.2 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2020-2025) &nbsp;7.3 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) by Country &nbsp;8.1.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Live Attenuated Influenza Vaccine (LAIV) &nbsp;10.3 Manufacturing Process Analysis of Live Attenuated Influenza Vaccine (LAIV) &nbsp;10.4 Industry Chain Structure of Live Attenuated Influenza Vaccine (LAIV) 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Live Attenuated Influenza Vaccine (LAIV) Distributors &nbsp;11.3 Live Attenuated Influenza Vaccine (LAIV) Customer 12 World Forecast Review for Live Attenuated Influenza Vaccine (LAIV) by Geographic Region &nbsp;12.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region &nbsp;12.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Forecast by Region (2026-2031) &nbsp;12.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Live Attenuated Influenza Vaccine (LAIV) Forecast by Type (2026-2031) &nbsp;12.7 Global Live Attenuated Influenza Vaccine (LAIV) Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Sanofi Pasteur &nbsp;13.1.1 Sanofi Pasteur Company Information &nbsp;13.1.2 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Sanofi Pasteur Main Business Overview &nbsp;13.1.5 Sanofi Pasteur Latest Developments &nbsp;13.2 AstraZeneca &nbsp;13.2.1 AstraZeneca Company Information &nbsp;13.2.2 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 AstraZeneca Main Business Overview &nbsp;13.2.5 AstraZeneca Latest Developments &nbsp;13.3 CSL &nbsp;13.3.1 CSL Company Information &nbsp;13.3.2 CSL Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 CSL Main Business Overview &nbsp;13.3.5 CSL Latest Developments &nbsp;13.4 Abbott &nbsp;13.4.1 Abbott Company Information &nbsp;13.4.2 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Abbott Main Business Overview &nbsp;13.4.5 Abbott Latest Developments &nbsp;13.5 GlaxoSmithKline &nbsp;13.5.1 GlaxoSmithKline Company Information &nbsp;13.5.2 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 GlaxoSmithKline Main Business Overview &nbsp;13.5.5 GlaxoSmithKline Latest Developments &nbsp;13.6 Serum Institute &nbsp;13.6.1 Serum Institute Company Information &nbsp;13.6.2 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Serum Institute Main Business Overview &nbsp;13.6.5 Serum Institute Latest Developments &nbsp;13.7 Fluenz Tetra &nbsp;13.7.1 Fluenz Tetra Company Information &nbsp;13.7.2 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Fluenz Tetra Main Business Overview &nbsp;13.7.5 Fluenz Tetra Latest Developments &nbsp;13.8 Cytiva &nbsp;13.8.1 Cytiva Company Information &nbsp;13.8.2 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Cytiva Main Business Overview &nbsp;13.8.5 Cytiva Latest Developments &nbsp;13.9 BioDiem &nbsp;13.9.1 BioDiem Company Information &nbsp;13.9.2 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 BioDiem Main Business Overview &nbsp;13.9.5 BioDiem Latest Developments &nbsp;13.10 FluMist &nbsp;13.10.1 FluMist Company Information &nbsp;13.10.2 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 FluMist Main Business Overview &nbsp;13.10.5 FluMist Latest Developments &nbsp;13.11 GSK &nbsp;13.11.1 GSK Company Information &nbsp;13.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 GSK Main Business Overview &nbsp;13.11.5 GSK Latest Developments &nbsp;13.12 ChangChun High & New Technology &nbsp;13.12.1 ChangChun High & New Technology Company Information &nbsp;13.12.2 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.12.3 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 ChangChun High & New Technology Main Business Overview &nbsp;13.12.5 ChangChun High & New Technology Latest Developments &nbsp;13.13 BCHT Biotechnology &nbsp;13.13.1 BCHT Biotechnology Company Information &nbsp;13.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications &nbsp;13.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 BCHT Biotechnology Main Business Overview &nbsp;13.13.5 BCHT Biotechnology Latest Developments 14 Research Findings and Conclusion

Report	Global Live Attenuated Influenza Vaccine (LAIV) Market Growth 2025-2031
Selected License	Single ID:LPI10960

Buyer Information

Order Summary